MKMalgorzata Kasztan

Malgorzata Kasztan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Malgorzata Kasztan has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A model of recurrent heat stress that causes kidney injury in mice

    by Hung Nguyen, Anna D. Montgomery, Cassidy Rehage, Nicholas Harris, Bryan K. Becker, Malgorzata Kasztan, Paul W. Sanders, Roxana C. Chicas, Subhashini Bolisetty, Kelly A. Hyndman

    Here we present a recurrent heat stress model that produces consistent increases in core temperature and dehydration with each event, leading to kidney injury in male and female mice. This robust and reproducible model demonstrates that repeated heat exposure drives sustained kidney injury, inflammation, and functional decline. It offers a valuable platform for mechanistic investigation and therapeutic development relevant to CKD of nontraditional origin.

  • Open Access

    Impact of renal iron overload on sickle cell nephropathy in a humanized mouse model

    by Mohammad O. Sako, Bryant J. Kane, Michael Booze, Savannah Walker, Margi Patel, Sirisha Swamigari, Hung Nguyen, Kelly A. Hyndman, Tanecia Mitchell, Subhashini Bolisetty, et al.

    SCD, an inherited hemolytic anemia, is associated with increased mortality from prolonged iron overload. Current interventional strategies are limited to the chelation of transfusion-mediated iron overload only, leaving kidney-specific, hemolysis-driven iron burden unaddressed. This study provided preclinical evidence that iron chelation prevents kidney-specific iron overload and subsequent kidney injury in a murine model of SCD. Thus, iron chelation of systemic- and transfusion-independent renal iron accumulation may slow the progression of SCD nephropathy.

  • Open Access

    Endothelin receptor antagonism in sickle cell disease: Is the time now?

    by Bryant J. Kane, Vimal K. Derebail, Malgorzata Kasztan

    Sickle cell disease (SCD) is a severe heritable hemoglobinopathy characterized by chronic hemolysis, episodic vaso-occlusion, and progressive multi-organ damage. Although hydroxyurea remains the most established disease-modifying therapy and that newer approaches such as L-glutamine, voxelotor, crizanlizumab, and gene therapy have expanded the therapeutic landscape, important limitations remain. These include incomplete efficacy, recent clinical or regulatory setbacks, as well as high cost and access barriers. Thus, safe, accessible, and mechanistically targeted treatments remain urgently needed, particularly for patients with progressive end-organ injury. Mounting evidence implicates the peptide endothelin-1 (ET-1) as a mediator of SCD pathology, and blockade of one of its primary receptors, endothelin receptor A (ET A ), may ameliorate several adverse effects. In humanized SCD mice, selective ET A antagonism provides robust nephroprotection, while Phase I clinical data suggest a favorable safety profile in addition to signals of improved albuminuria and vascular function. In parallel, selective ET A antagonists have rapidly advanced owing to multiple FDA approvals for proteinuric kidney diseases outside the context of SCD, in addition to approvals as antihypertensives. Here, we highlight emerging evidence supporting endothelin pathway blockade as a potential targeted therapy for complications such as sickle cell nephropathy, vasculopathy, and pain, while discussing key considerations for future trials.

  • Open Access

    Addressing the pathophysiology of venous thrombosis and chronic kidney disease in sickle cell trait using a mouse model

    by Fatima Trebak, Mohammad O. Sako, Steven P. Grover, Karnsasin Seanoon, Izabela Pawlinski, Chatphatai Moonla, Michael W. Henderson, Vimal K. Derebail, Dougald M. Monroe, Patrick Ellsworth, et al.

    Sickle cell trait (SCT) is present in participants who possess a single copy of the βS-globin gene mutation. Although most affected individuals are asymptomatic, SCT is a well-established risk factor for venous thrombosis and renal complications, including chronic and end-stage kidney disease. After prolonged hypoxia, SCT red blood cells (RBCs) can undergo sickling, and hypoxia-mediated RBC sickling can be enhanced by cellular dehydration, hyperosmolarity, and/or acidosis. Some or all of these conditions may be encountered in the nidus of venous thrombi and in the medulla of the kidney. We sought to determine whether Townes sickle trait (AS) mice develop kidney dysfunction and manifest enhanced venous thrombosis. We demonstrated that the harsh environment within the inner medulla induces RBC sickling in vitro and in vivo and is associated with kidney-related pathologies, including impaired urinary concentration, albuminuria, and declining renal function, closely mimicking those seen in human SCT. In the inferior vena cava model of venous thrombosis, extreme and prolonged hypoxia in the core of RBC-rich venous thrombi resulted in irreversible RBC sickling and larger clots in Townes AS mice than AA controls (littermates expressing hemoglobin A only). Our results support the use of Townes AS mice in future studies investigating mechanisms of venous thrombosis and chronic kidney disease in SCT.


  • Open Access

    Natural history and variability in albuminuria in pediatric and murine sickle cell anemia

    by Malgorzata Kasztan, Inmaculada Aban, Kayla Baker, Michael Ho, Chibuzo Ilonze, Jeffrey Lebensburger

    It is critical to characterize the natural history of albuminuria in patients with sickle cell anemia (SCA); however, these data are currently lacking and affecting evidence-based guidelines. We performed a natural history study of the development of pediatric albuminuria. We identified participants with hemoglobin SS/SB0 thalassemia ≥5 years with albumin to creatinine ratio (ACR) measurements performed at a steady-state clinic visit. Participants were characterized as either persistent, intermittent, or never albuminuria. We determined the prevalence of persistent albuminuria, use of ACR ≥100 mg/g as a predictor, and variation in ACR measurements. We mirrored this study to determine the variation in albuminuria measurements in the SCA murine model. Among 355 participants with HbSS/SB0 thalassemia with 1728 ACR measurements, we identified 17% with persistent and 13% with intermittent albuminuria. Thirteen percent of participants with persistent albuminuria developed an abnormal ACR before 10 years of age. A single ACR measurement ≥100 mg/g was associated with 55.5 times (95% confidence interval, 12.3-527) higher odds of having persistent albuminuria. Among participants with ACR ≥100 mg/g, we identified significant variability in the results of repeated measurements. The median ACR at the initial and next measurements were 175.8 mg/g (interquartile range [IQR], 135-242) and 117.3 mg/g (IQR, 64-292). The human variability in ACR was mirrored by ∼20% variability in albuminuria in murine model. This evidence suggests adopting standards for repeating ACR measurements, consider screening for ACR before 10 years of age, and using an ACR >100 mg/g as a risk factor for progression. Pediatric and murine renoprotective clinical trials need to consider the high variability in repeated ACR measurements.


  • Open Access

    Factor XII contributes to thrombotic complications and vaso-occlusion in sickle cell disease

    by Erica M. Sparkenbaugh, Michael W. Henderson, Megan Miller-Awe, Christina Abrams, Anton Ilich, Fatima Trebak, Nirupama Ramadas, Shantel Vital, Dillon Bohinc, Kara L. Bane, et al.

    A hypercoagulable state, chronic inflammation, and increased risk of venous thrombosis and stroke are prominent features in patients with sickle cell disease (SCD). Coagulation factor XII (FXII) triggers activation of the contact system that is known to be involved in both thrombosis and inflammation, but not in physiological hemostasis. Therefore, we investigated whether FXII contributes to the prothrombotic and inflammatory complications associated with SCD. We found that when compared with healthy controls, patients with SCD exhibit increased circulating biomarkers of FXII activation that are associated with increased activation of the contact pathway. We also found that FXII, but not tissue factor, contributes to enhanced thrombin generation and systemic inflammation observed in sickle cell mice challenged with tumor necrosis factor α. In addition, FXII inhibition significantly reduced experimental venous thrombosis, congestion, and microvascular stasis in a mouse model of SCD. Moreover, inhibition of FXII attenuated brain damage and reduced neutrophil adhesion to the brain vasculature of sickle cell mice after ischemia/reperfusion induced by transient middle cerebral artery occlusion. Finally, we found higher FXII, urokinase plasminogen activator receptor, and αMβ2 integrin expression in neutrophils of patients with SCD compared with healthy controls. Our data indicate that targeting FXII effectively reduces experimental thromboinflammation and vascular complications in a mouse model of SCD, suggesting that FXII inhibition may provide a safe approach for interference with inflammation, thrombotic complications, and vaso-occlusion in patients with SCD.


  • Endothelin A receptor antagonist attenuated renal iron accumulation in iron overload heme oxygenase-1 knockout mice

    by Elizabeth Saurage, Parker Ross Davis, Rachel Meek, David M. Pollock, Malgorzata Kasztan

    Progressive iron accumulation and renal impairment are prominent in both patients and mouse models of sickle cell disease (SCD). Endothelin A receptor (ETA) antagonism prevents this iron accumulation phenotype and reduces renal iron deposition in the proximal tubules of SCD mice. To better understand the mechanisms of iron metabolism in the kidney and the role of the ETA receptor in iron chelation and transport, we studied renal iron handling in a nonsickle cell iron overload model, heme oxygenase-1 ( Hmox-1−/−) knockout mice. We found that Hmox-1−/− mice had elevated plasma endothelin-1 (ET-1), cortical ET-1 mRNA expression, and renal iron content compared with Hmox-1+/+ controls. The ETA receptor antagonist, ambrisentan, attenuated renal iron deposition, without any changes to anemia status in Hmox-1−/− mice. This was accompanied by reduced urinary iron excretion. Finally, ambrisentan had an important iron recycling effect by increasing the expression of the cellular iron exporter, ferroportin-1 (FPN-1), and circulating total iron levels in Hmox-1−/− mice. These findings suggest that the ET-1/ETA signaling pathway contributes to renal iron trafficking in a murine model of iron overload.


  • High molecular weight kininogen contributes to early mortality and kidney dysfunction in a mouse model of sickle cell disease

    by Erica M. Sparkenbaugh, Malgorzata Kasztan, Michael W. Henderson, Patrick Ellsworth, Parker Ross Davis, Kathryn J. Wilson, Brandi Reeves, Nigel S. Key, Sidney Strickland, Keith McCrae, et al.


  • Open Access

    Sex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemia

    by Malgorzata Kasztan, Inmaculada Aban, Suraj P. Hande, David M. Pollock, Jeffrey D. Lebensburger


  • Impact of ET-1 and sex in glomerular hyperfiltration in humanized sickle cell mice

    by Malgorzata Kasztan, David M. Pollock

    Hyperfiltration, highly prevalent early in sickle cell disease (SCD), is in part driven by an increase in ultrafiltration coefficient (Kf). The increases in Kf may be due to enlarged filtration surface area and/or increased glomerular permeability (Palb). Previous studies have demonstrated that endothelin-1 (ET-1) contributes to Palb changes in models of diabetes and SCD. Thus, we performed longitudinal studies of renal function to determine the relationship between ET-1 and glomerular size and Palb that may contribute to hyperfiltration in humanized sickle cell (HbSS) and control (HbAA) mice 8 to 32 weeks of age. HbSS mice were characterized by significant increases in plasma and glomerular ET-1 expression in both sexes although this increase was significantly greater in males. HbSS glomeruli of both males and females presented with a progressive and significant increase in glomerular size, volume, and Kf. During the onset of hyperfiltration, plasma and glomerular ET-1 expression were associated with a greater increase in glomerular size and Kf in HbSS mice, regardless of sex. The pattern of Palb augmentation during the hyperfiltration was also associated with an increase in glomerular ET-1 expression, in both male and female HbSS mice. However, the increase in Palb was significantly greater in males and delayed in time in females. Additionally, selective endothelin A (ETA) receptor antagonist prevented hyperfiltration in HbSS, regardless of sex. These results suggest that marked sex disparity in glomerular hyperfiltration may be driven, in part, by ET-1-dependent ultra-structural changes in filtration barrier components contributing to glomerular hyperfiltration in HbSS mice.